Dendrite Announces New Hire Option Grants.

BEDMINSTER, N.J. -- Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), as amended October 14, 2003, Dendrite International, Inc. (NASDAQ: DRTE) today announced that stock options covering an aggregate of 165,000 shares were granted to thirteen employees on January 27, 2005; options covering an aggregate of 15,000 shares were granted to three employees on October 18, 2004; and options covering 10,000 shares were granted to one employee on October 1, 2004, as an inducement to entering into employment with the Company.

All such option grants were made to non-executive officer employees under the Company's New Hire Option Grant Authorization Plan on terms that include a 10 year duration and an exercise price equal to the closing price of Dendrite's stock on the business day immediately preceding the date of grant. The shares issued in January vest on June 30, 2005 and the shares issued in October vested on December 31, 2004. For all grants, the right to sell the underlying shares accrues in either three, or four, equal installments on each of the first three, or four, anniversaries of the date of grant.

About Dendrite

Pharmaceutical and other Life Sciences companies can look to Dendrite as their first source for expert, integrated global solutions that enhance the effectiveness of marketing, sales and clinical trial programs. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.